tldrdailynews.com logo

Novo Nordisk fights back as rival offers $49 weight‑loss semaglutide

1 min read
Source: Financial Times
Novo Nordisk fights back as rival offers $49 weight‑loss semaglutide
Photo: Financial Times
TL;DR

Novo Nordisk says Hims & Hers’ new $49/month, compounded semaglutide version of Wegovy is illegal mass compounding and unsafe, pledging legal action; the FDA has warned against copycat GLP‑1 drugs. The move intensifies price competition in obesity drugs, with Novo forecasting up to a 13% drop in net sales and shares for Novo Nordisk and Lilly slipping.

Topics:business#business#fda#hims-and-hers#novo-nordisk#semaglutide#wegovy
Share this article
  1. Novo Nordisk hits out at rival Hims & Hers over cheaper weight-loss pill  Financial Times
  2. Novo Nordisk says it will take legal action after Hims & Hers reveals $49 copy of Wegovy pill  CNBC
  3. Cheaper, Generic Weight-Loss Drugs Are Coming  Bloomberg
  4. Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month  Hims Investor Relations
  5. Hims launches $49 compounded copy of Wegovy weight-loss pill  Yahoo Finance

Want the full story? Read the original reporting

Read on Financial Times